These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15909775)

  • 1. Review of contrast-induced nephropathy and current use of N-acetylcysteine (NAC).
    Anwar M; Ledger S
    CANNT J; 2005; 15(1):33-8,quiz 38-9. PubMed ID: 15909775
    [No Abstract]   [Full Text] [Related]  

  • 2. N-acetylcysteine use to prevent contrast medium-induced nephropathy: premature phase III trials.
    Stenstrom DA; Muldoon LL; Armijo-Medina H; Watnick S; Doolittle ND; Kaufman JA; Peterson DR; Bubalo J; Neuwelt EA
    J Vasc Interv Radiol; 2008 Mar; 19(3):309-18. PubMed ID: 18295688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The use of acetylcysteine for preventing contrast-induced nephropathy].
    Schaad N; Barghouth G
    Rev Med Suisse; 2005 Jun; 1(25):1693-6. PubMed ID: 16117036
    [No Abstract]   [Full Text] [Related]  

  • 4. Sodium bicarbonate, N-acetylcysteine, and saline for the prevention of contrast-induced nephropathy.
    Bouzas-Mosquera A; Recio-Mayoral A
    Am Heart J; 2008 Apr; 155(4):e31. PubMed ID: 18371455
    [No Abstract]   [Full Text] [Related]  

  • 5. N-acetylcysteine and contrast-induced nephropathy.
    Ritz E
    N Engl J Med; 2006 Oct; 355(14):1499; author reply 1499-500. PubMed ID: 17024738
    [No Abstract]   [Full Text] [Related]  

  • 6. Preventing nephropathy induced by contrast medium.
    Tepel M
    N Engl J Med; 2006 Apr; 354(17):1853-5; author reply 1853-5. PubMed ID: 16642596
    [No Abstract]   [Full Text] [Related]  

  • 7. A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine.
    Lepor NE
    Rev Cardiovasc Med; 2003; 4 Suppl 1():S15-20. PubMed ID: 12556733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics.
    Coyle LC; Rodriguez A; Jeschke RE; Simon-Lee A; Abbott KC; Taylor AJ
    Am Heart J; 2006 May; 151(5):1032.e9-12. PubMed ID: 16644332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study.
    Ferrario F; Barone MT; Landoni G; Genderini A; Heidemperger M; Trezzi M; Piccaluga E; Danna P; Scorza D
    Nephrol Dial Transplant; 2009 Oct; 24(10):3103-7. PubMed ID: 19549691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial.
    Ozcan EE; Guneri S; Akdeniz B; Akyildiz IZ; Senaslan O; Baris N; Aslan O; Badak O
    Am Heart J; 2007 Sep; 154(3):539-44. PubMed ID: 17719303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-acetylcysteine and contrast-induced nephropathy.
    Wolak A; Cafri C; Zahger D
    N Engl J Med; 2006 Oct; 355(14):1498; author reply 1499-500. PubMed ID: 17024739
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevention of contrast-induced renal dysfunction by N-acetylcysteine. Truth or myth?
    Billinger M; Hess OM; Meier B
    Eur Heart J; 2004 Feb; 25(3):188-9. PubMed ID: 14972417
    [No Abstract]   [Full Text] [Related]  

  • 13. Has acetylcysteine use changed the incidence of contrast nephropathy in hospitalized patients? A before-after study.
    Shah SJ; Hsu CY
    Am J Med; 2004 Dec; 117(12):948-52. PubMed ID: 15629734
    [No Abstract]   [Full Text] [Related]  

  • 14. Investigating the volume status before contrast nephropathy studies.
    Toprak O; Cirit M
    Nephrol Dial Transplant; 2005 Feb; 20(2):464; author reply 464-6. PubMed ID: 15673702
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN).
    Ng TM; Shurmur SW; Silver M; Nissen LR; O'Leary EL; Rigmaiden RS; Cieciorka M; Porter LL; Ineck BA; Kline ME; Puumala SE
    Int J Cardiol; 2006 May; 109(3):322-8. PubMed ID: 16039733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrast-induced nephropathy: a clinical and evidence-based approach.
    Tepel M; Aspelin P; Lameire N
    Circulation; 2006 Apr; 113(14):1799-806. PubMed ID: 16606801
    [No Abstract]   [Full Text] [Related]  

  • 17. N-acetylcysteine and sodium bicarbonate versus N-acetylcysteine and standard hydration for the prevention of radiocontrast-induced nephropathy following coronary angiography.
    Schmidt P; Pang D; Nykamp D; Knowlton G; Jia H
    Ann Pharmacother; 2007 Jan; 41(1):46-50. PubMed ID: 17190844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials.
    Zagler A; Azadpour M; Mercado C; Hennekens CH
    Am Heart J; 2006 Jan; 151(1):140-5. PubMed ID: 16368307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-acetylcysteine and contrast-induced nephropathy.
    Balderramo DC
    N Engl J Med; 2006 Oct; 355(14):1498-9; author reply 1499-500. PubMed ID: 17024740
    [No Abstract]   [Full Text] [Related]  

  • 20. N-acetylcysteine and contrast-induced nephropathy.
    Aguiar-Souto P; Valero-González S; Domínguez JF
    N Engl J Med; 2006 Oct; 355(14):1497-8; author reply 1499-500. PubMed ID: 17021328
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.